Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1–9.

Article  Google Scholar 

Sittenfeld SMC, Zabor EC, Hamilton SN, Kuerer HM, El-Tamer M, Naoum GE, et al. A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1–2N1 breast cancer. Cancer. 2022;128:3057–66.

Article  CAS  PubMed  Google Scholar 

Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann Oncol. 2022;33:769–85.

Article  PubMed  Google Scholar 

Narayan P, Wahby S, Gao JJ, Amiri-Kordestani L, Ibrahim A, Bloomquist E, et al. FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res. 2020;26:2284–9.

Article  CAS  PubMed  Google Scholar 

Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33:534–43.

Article  CAS  PubMed  Google Scholar 

Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:511–20.

Article  CAS  PubMed  Google Scholar 

Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020;31:569–81.

Article  CAS  PubMed  Google Scholar 

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, et al. Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 2019;25:1437.

Article  PubMed  Google Scholar 

Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Núñez NG, et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell. 2022;185:1189-1207.e25.

Article  CAS  PubMed  Google Scholar 

Li H, Yang P, Wang J, Zhang J, Ma Q, Jiang Y, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol. 2022;15:2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santoni M, Romagnoli E, Saladino T, Foghini L, Guarino S, Capponi M, et al. Triple negative breast cancer: key role of tumor-associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. Biochim Biophys Acta Rev Cancer. 2018;1869:78–84.

Article  CAS  PubMed  Google Scholar 

Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7:737–50.

Article  CAS  PubMed  Google Scholar 

Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, et al. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat Commun. 2019;10:5499.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Q, Chen S, Hu Y, Huang W. Landscape of immune microenvironment under immune cell infiltration pattern in breast cancer. Front Immunol. 2021;12: 711433.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, et al. The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges. Theranostics. 2019;9:1303–22.

Article  PubMed  PubMed Central  Google Scholar 

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.

Article  PubMed  PubMed Central  Google Scholar 

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.

Article  PubMed  Google Scholar 

Mohammadi A, Mirza-Aghazadeh-Attari M, Faeghi F, Homayoun H, Abolghasemi J, Vogl TJ, et al. Tumor microenvironment, radiology, and artificial intelligence: should we consider tumor periphery? J Ultrasound Med. 2022;41:3079–90.

Article  PubMed  Google Scholar 

Su G-H, Xiao Y, Jiang L, Zheng R-C, Wang H, Chen Y, et al. Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. J Transl Med. 2022;20:471.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs. 2022;31:567–91.

Article  CAS  PubMed  Google Scholar 

Ruonan Z, Yajing Y, Wenjing D, Mingen L, Jing H, Xinchao Z, et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci USA. 2022;119(8): e2114851119.

Article  Google Scholar 

Maria V-D, Valentina G, Anna T, Giancarlo B, Antonino M, Simon S, et al. Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: results of the phase II GIADA trial. Clin Cancer Res. 2022;28(2):308–17.

Article  Google Scholar 

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5:74–82.

Article  PubMed  Google Scholar 

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet Lond Engl. 2020;396:1817–28.

Article  Google Scholar 

Franzén AS, Raftery MJ, Pecher G. Implications for immunotherapy of breast cancer by understanding the microenvironment of a solid tumor. Cancers. 2022;14:3178.

Article  PubMed  PubMed Central  Google Scholar 

Sofopoulos M, Fortis SP, Vaxevanis CK, Sotiriadou NN, Arnogiannaki N, Ardavanis A, et al. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. Cancer Immunol Immunother. 2019;68:1733–45.

Article  CAS  PubMed  Google Scholar 

Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue M-Z, et al. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002–14.

Article  CAS  PubMed  Google Scholar 

Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S, Coukos G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol. 2020;21:e419–30.

Article  CAS  PubMed  Google Scholar 

Zhao S, Ma D, Xiao Y, Li X-M, Ma J-L, Zhang H, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist. 2020;25:e1481–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32:1236–44.

Article  CAS  PubMed  Google Scholar 

Han X, Cao W, Wu L, Liang C. Radiomics assessment of the tumor immune microenvironment to predict outcomes in breast cancer. Front Immunol. 2021;12: 773581.

Article  CAS  PubMed  Google Scholar 

Huang Y, Wei L, Hu Y, Shao N, Lin Y, He S, et al. Multi-parametric mri-based radiomics models for predicting molecular subtype and androgen receptor expression in breast cancer. Front Oncol. 2021;11: 706733.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180–91.

Article  CAS  PubMed  Google Scholar 

Hong M, Fan S, Yu Z, Gao C, Fang Z, Du L, et al. Evaluating upstaging in ductal carcinoma in situ using preoperative MRI-based radiomics. J Magn Reson Imaging. 2023;58:454–63.

Article  PubMed  Google Scholar 

Javed AA, Zhu Z, Kinny-Köster B, Habib JR, Kawamoto S, Hruban RH, et al. Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature. Diagn Interv Imaging. 2023;S2211–5684(23):00155–9.

Google Scholar 

Ligero M, Jordi-Ollero O, Bernatowicz K, Garcia-Ruiz A, Delgado-Muñoz E, Leiva D, et al. Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Eur Radiol. 2021;31:1460–70.